Kotak Private Equity invested in Eyestem, a Bengaluru based cell therapy company. Eyestem has raised this funding from Kotak for using its patented flagship product, EyecyteRPE, to treat dry age-related macular degeneration through first in man clinical trials, according to the company's press release.
Argus Partners advised
2020-12-30
This deal report is based on a firm's press release and may be only partially complete. Some firms or names of advisers may be therefore be missing.
No comments yet: share your views